Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation
Recent scientific studies indicate a significant association between GLP-1 receptor agonists and NAION, with evidence suggesting that these drugs may induce ischemic optic neuropathy through mechanisms such as vascular dysregulation, hypotension, or direct effects on optic nerve blood supply. The FDA has acknowledged reports of vision loss linked to these medications, and legal claims are based on the temporal relationship between drug use and NAION onset, supported by clinical findings and adverse event reports.
146
Pending actions
146
Total actions filed
Active
Status
12/15/2025
Established
Filing deadline
The court order from December 2025 does not specify an explicit filing deadline but indicates ongoing case management with expert discovery closing in March 2026, and expert depositions due by April 10, 2026. The statute of limitations varies by jurisdiction but generally aligns with the filing deadlines set by the court's case management schedule.
Who qualifies
Plaintiffs must demonstrate a diagnosis of NAION confirmed by medical professionals, with recent or ongoing use of GLP-1 receptor agonists such as Ozempic, Wegovy, Saxenda, or Trulicity. The typical dosage involved is standard therapeutic doses, including weekly injections of Ozempic and Wegovy (ranging from 0.25 mg to 2 mg). The onset of NAION symptoms generally occurs within 2-4 months of initiating therapy, with some cases reported up to 6 months. Plaintiffs are required to show that they used the drug as prescribed, with no alternative explanations for their optic nerve injury, supported by medical records.
Products involved
- Ozempic (semaglutide)
- Wegovy (semaglutide)
- Saxenda (liraglutide)
- Trulicity (dulaglutide)
Alleged injuries
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
Bellwether trials
Bellwether trials are scheduled to commence in late 2026, with some sources indicating trials starting around December 2026. The first trials are expected to focus on cases with clear temporal links between drug use and NAION onset.
Settlement landscape
While specific settlement amounts are not publicly disclosed, estimates for similar MDL cases involving drug-induced vision loss suggest potential settlements up to $300,000 per case. The ongoing litigation and leadership appointments imply that substantial settlements or verdicts may be forthcoming, but no definitive figures are available yet.
Lead counsel
- Jason Goldstein, Parker Waichman LLP
This page is generated from the official JPML pending-MDL report and public court records, refreshed monthly. It is provided for attorney reference and is not legal advice.
